



(51) International Patent Classification:

C07C 323/57 (2006.01) A61K 31/10 (2006.01)
C07C 321/20 (2006.01) A61P 11/00 (2006.01)
A61K 31/167 (2006.01) A61P 37/08 (2006.01)

(21) International Application Number:

PCT/US2009/049621

(22) International Filing Date:

2 July 2009 (02.07.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/078,311 3 July 2008 (03.07.2008) US

(71) Applicant (for all designated States except US): **AMIRA PHARMACEUTICALS, INC.** [US/US]; 9535 Waples Street, Suite 100, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HUTCHINSON, John, Howard** [US/US]; 5948 Via Zurita, La Jolla, CA 92037 (US). **SEIDERS, Thomas, Jon** [US/US]; 5257 Soledad Mountain Road, San Diego, CA 92109 (US). **WANG, Bowei** [US/US]; 5025 Manor Ridge Lane, San

Diego, CA 92130 (US). **ARRUDA, Jeannie, M.** [US/US]; 3611 Florida St. #4, San Diego, CA 92104 (US). **STEARNS, Brian, Andrew** [US/US]; 3339 32nd Street, San Diego, CA 92104 (US).

(74) Agents: **AKHAVAN, Ramin** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]


(54) Title: ANTAGONISTS OF PROSTAGLANDIN D₂ RECEPTORS

Figure 1

(57) Abstract: Described herein are compounds that are antagonists of PGD₂ receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD₂ receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD₂-dependent or PGD₂-mediated conditions or diseases.



ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

(88) Date of publication of the international search report:

29 April 2010